image
Healthcare - Medical - Devices - NASDAQ - CR
$ 31.3
-3.1 %
$ 903 M
Market Cap
-10.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ESTA stock under the worst case scenario is HIDDEN Compared to the current market price of 31.3 USD, Establishment Labs Holdings Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ESTA stock under the base case scenario is HIDDEN Compared to the current market price of 31.3 USD, Establishment Labs Holdings Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ESTA stock under the best case scenario is HIDDEN Compared to the current market price of 31.3 USD, Establishment Labs Holdings Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ESTA

image
$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
166 M REVENUE
0.53%
-50 M OPERATING INCOME
23.13%
-84.6 M NET INCOME
-7.76%
-58.5 M OPERATING CASH FLOW
33.89%
-15.6 M INVESTING CASH FLOW
36.40%
126 M FINANCING CASH FLOW
46.00%
44.5 M REVENUE
10.66%
-18.7 M OPERATING INCOME
-42.10%
-34.5 M NET INCOME
-107.00%
-20.7 M OPERATING CASH FLOW
-66.51%
-1.82 M INVESTING CASH FLOW
34.21%
74.5 M FINANCING CASH FLOW
266139.29%
Balance Sheet Establishment Labs Holdings Inc.
image
Current Assets 243 M
Cash & Short-Term Investments 90.3 M
Receivables 65 M
Other Current Assets 87.7 M
Non-Current Assets 104 M
Long-Term Investments 0
PP&E 83.6 M
Other Non-Current Assets 20.2 M
26.05 %18.74 %25.28 %24.10 %5.83 %Total Assets$346.8m
Current Liabilities 68.3 M
Accounts Payable 44.8 M
Short-Term Debt 1.51 M
Other Current Liabilities 22 M
Non-Current Liabilities 225 M
Long-Term Debt 8.41 M
Other Non-Current Liabilities 217 M
15.24 %7.49 %2.86 %73.89 %Total Liabilities$293.7m
EFFICIENCY
Earnings Waterfall Establishment Labs Holdings Inc.
image
Revenue 166 M
Cost Of Revenue 56.5 M
Gross Profit 110 M
Operating Expenses 160 M
Operating Income -50 M
Other Expenses 34.6 M
Net Income -84.6 M
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)166m(56m)110m(160m)(50m)(35m)(85m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
65.97% GROSS MARGIN
65.97%
-30.11% OPERATING MARGIN
-30.11%
-50.95% NET MARGIN
-50.95%
-159.33% ROE
-159.33%
-24.39% ROA
-24.39%
-17.84% ROIC
-17.84%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Establishment Labs Holdings Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -84.6 M
Depreciation & Amortization 7.58 M
Capital Expenditures -6.11 M
Stock-Based Compensation 14.4 M
Change in Working Capital 0
Others 6.28 M
Free Cash Flow -64.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Establishment Labs Holdings Inc.
image
Wall Street analysts predict an average 1-year price target for ESTA of $70.3 , with forecasts ranging from a low of $45 to a high of $110 .
ESTA Lowest Price Target Wall Street Target
45 USD 43.77%
ESTA Average Price Target Wall Street Target
70.3 USD 124.55%
ESTA Highest Price Target Wall Street Target
110 USD 251.44%
Price
Max Price Target
Min Price Target
Average Price Target
11011010010090908080707060605050404030302020May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Establishment Labs Holdings Inc.
image
Sold
0-3 MONTHS
4.5 K USD 1
3-6 MONTHS
4.52 M USD 1
6-9 MONTHS
164 K USD 1
9-12 MONTHS
513 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Establishment Labs Notes Presentation of 5-Year Results from Motiva U.S. IDE Study at The Aesthetic MEET 2025 NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include five-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the re. businesswire.com - 3 weeks ago
Establishment Labs® Announces Meghan Trainor as Brand Partner Following Her Breast Augmentation with Motiva Implants® The campaign is the first-of-its-kind partnership and follows the US FDA approval of Motiva Implants®  NEW YORK , March 6, 2025 /PRNewswire/ -- Establishment Labs® Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a partnership with GRAMMY Award-winning hitmaker Meghan Trainor. Meghan recently received Motiva Implants® after careful consideration and research. prnewswire.com - 1 month ago
Establishment Labs Holdings Inc. (ESTA) Q4 2024 Earnings Call Transcript Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Raj Denhoy - CFO Juan Chacón-Quirós - CEO Peter Caldini - President Conference Call Participants Anthony Petrone - Mizuho Group Allen Gong - JPMorgan Josh Jennings - TD Cowen Marie Thibault - BTIG Joanne Wuensch - Citibank Matt Taylor - Jefferies Harrison Parsons - Stephens Inc Operator Good afternoon. Welcome to Establishment Labs Fourth Quarter 2024 Earnings Call. seekingalpha.com - 1 month ago
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Lags Revenue Estimates Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.79 per share a year ago. zacks.com - 1 month ago
Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and la. businesswire.com - 1 month ago
Establishment Labs to Present at Citi's 2025 Unplugged Medtech and Life Sciences Access Day NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in a fireside chat at Citi's 2025 Unplugged Medtech and Life Sciences Access Day. Juan José Chacón-Quirós, Chief Executive Officer and Founder; Peter Caldini, President; and Raj Denhoy, Chief Financial Officer, are scheduled to present on Thursday,. businesswire.com - 1 month ago
Establishment Labs Launches Preservé™ NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced it has launched Preservé™ in Brazil, the first country in its global rollout. Preservé is the second product in the Company's minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech®, Establishment Labs' minimally invasive experience. “The. businesswire.com - 1 month ago
Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26 NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. businesswire.com - 1 month ago
Establishment Labs to Present at the 43rd Annual J.P. Morgan Healthcare Conference NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 3:45 p.m. Pacific Time. A live webcast of the presentation. businesswire.com - 3 months ago
Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Rajbir Denhoy - Chief Financial Officer Juan Jose - CEO and Founder Conference Call Participants Allen Gong - JPMorgan Matt Taylor - Jefferies Sam Eiber - BTIG Anthony Pettinari - Citi Josh Jennings - TD Cowen Anthony Petrone - Mizuho Group Operator Good afternoon. Welcome to Establishment Labs Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 5 months ago
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Misses Revenue Estimates Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.12 per share a year ago. zacks.com - 5 months ago
Establishment Labs Announces $50 Million Registered Direct Offering NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for a. businesswire.com - 5 months ago
8. Profile Summary

Establishment Labs Holdings Inc. ESTA

image
COUNTRY CR
INDUSTRY Medical - Devices
MARKET CAP $ 903 M
Dividend Yield 0.00%
Description Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Contact Building B15 and 25, Alajuela, https://www.establishmentlabs.com
IPO Date July 19, 2018
Employees 1018
Officers Mr. Salvador Santos Dada Head of Special Projects Mr. Filippo Caldini Interim Chief Executive Officer & President Mr. Juan Jose Chacon Quiros Founder & Executive Director Ms. Rosalyn Cole d'Incelli SVice President of Global Clinical, Medical & US Regulatory Affairs Mr. Jeff Ehrhardt Senior Vice President & GM of North America Mr. S. Ross Mansbach General Counsel, Chief Compliance Officer & Chief Human Resources Officer Mr. Roberto de Mezerville Chief Technology Officer Mr. Ivan Bilic Senior Vice President of Commercial Operations - OUS Mr. Rajbir Singh Denhoy Chief Financial Officer Ms. Neeta Toprani Corporate Secretary